Treatment for Erectile Dysfunction

Viagra and Levitra feature rapid-onset of action, whereas Cialis has the long window of opportunity for use. Maximum levels in the bloodstream are reached within 45 minutes with Levitra, an hour and 10 minutes with Sildenafil, and 2 hours with Tadalafil. Conversely, the half-life of Viagra is 4 hours, for vardenafil 4 to 5 hours, and for Cialis 17 to 21 hours.

• PDE5 inhibitors require sexual arousal to work effectively.
• They are contraindicated with nitrates for chest pain.
• Possible side effects include headaches and flushing.
• These medications do not cause an erection without stimulation.
• Effectiveness varies among individuals tested during clinical trials.
• Consult a doctor before starting any ED medication.

In young men, one study has shown a preference for Cialis over sildenafil. The mean age of the patients was only 54 years, and outcomes were not well defined. In another study, looking at prescription refill rates, sildenafil was associated with a higher likelihood of refilling the initial prescription compared to vardenafil or tadalafil, which had a significantly lower odds of prescription refill.

• Natural supplements like ginseng are claimed to help ED.
• Evidence supporting supplements is limited and inconsistent.
• Some herbal remedies may interact with medications.
• Always consult a doctor before using supplements.
• Lifestyle changes are often more effective than herbal supplements.
• Beware of unregulated supplements and false claims.

It is recommended that prior to proceeding with other therapies, patients reporting failure of their PDE5 inhibitors should be evaluated to determine whether the trial was adequate. This would include discussion of fatty food ingestion, which is important with sildenafil, and specific patient population such as prostatectomy and diabetes. Furthermore, patients should be encouraged to continue attempts at intercourse up to the eighth to tenth dose of PDE5 inhibitor as improvements in success rate are seen up to the eighth to tenth dose.

What Tests Will a Urologist Do if I Have ED?

Patterns of care may shift away from surgical and device therapies provided by urologists and toward pharmacologic treatments and/or multidisciplinary approaches. With men increasingly seeking to preserve sexual function and quality of life as they age, the treatment of ED will take on even greater importance in the years to come. ED is defined as the persistent “inability to achieve or maintain an erection sufficient for satisfactory sexual performance.” The experience of ED may vary based on patients’ and partners’ perceptions and expectations about erectile function and sexual performance. As the public has become more aware of ED, the reported prevalence and severity of this condition have increased. Comprehensive questionnaires have been developed (e.g., the International Index of Erectile Function (IIEF)) to define ED presence, severity, and response to treatment.

Respiratory Disorders

Symptom-based definitions are rapidly replacing the routine use of physiologic measures of erectile function such as penile tumescence. The definition of ED provided by the National Institutes of Health does not include the duration of dysfunction; subsequent recommendations by the World Health Organization specify a three-month minimum duration of symptoms to establish that diagnosis except in cases of trauma or surgically induced ED. Objective physiologic testing may be used to support the diagnosis of ED, but it cannot substitute for the patient’s self-report in establishing the diagnosis. The diagnosis of ED requires a detailed sexual and medical history, physical examination, and laboratory tests. Self-administered questionnaires are useful adjuncts to the case history, but they are not sufficient to diagnose ED correctly or treat it safely. Risk exposure is important to consider in the PDE5 inhibitors. Cardiovascular diseases may be a contraindication to treatment, as severely impaired patients may run the risk of a cardiac complication related to vigorous sexual activity.

Likewise, patients actively taking nitrates, including nitroglycerine and other agents, are contraindicated from receiving prescriptions for PDE5 inhibitor. Relative cenforce 100 soft contraindications to the use of PDE5 inhibitor include alpha-adrenergic antagonists. Visual disturbances can be seen with sildenafil (blue haze to the visual field) as a result of inhibition of the PDE6 enzyme.

Choosing your ED drug

Men have demonstrated a strong preference for oral treatments even if they have low efficacy. Appropriate treatment options should be applied in a step-wise fashion, balancing invasiveness and risk versus efficacy. If possible, the partner should be involved in the decision-making. The decision depends on the patient preferences and expectations as well as the experience and judgment of the physician. Oral phosphodiesterase type-5 inhibitors are first line therapy.

Fungal Infections

The efficacy of sildenafil (Viagra), vardenafil (Levitra), and tadalafil (Cialis) are very similar. All drugs induce significant increases in erectile function at their highest dose. In general, an intermediate dose should be administered first to assess side effects. As long as side effects are minimal, patient should increase to the maximum recommended dosage (100 milligrams for Viagra, 20 milligrams for Levitra, vardenafil best price and 20 milligrams for Cialis. Because efficacy is very similar amongst the three agents, side effects and time-to-onset will be the main distinguishing factors. A very rare but more serious visual complication is shared by all PDE5 inhibitors. This would be non-arteritic anterior ischemic optic neuropathy (NAION). A number of cases have been reported and generally risk factors for this very rare form of blindness are severe cardiovascular conditions. In summary, men at high-risk for cardiovascular disease with congestive heart failure or unstable angina should not receive treatment for sexual dysfunction until their cardiac condition has stabilized. The FDA advises patients to stop taking these medicines and call a doctor immediately, if they experience sudden or decrease vision loss in one or both eyes. Furthermore, patients taking or considering taking these products should inform their healthcare professionals if they have ever had severe loss of vision, which may reflect a prior episode of NAION.

• ED is often a sign of underlying health problems.
• Cardiovascular health directly affects erectile function.
• Managing chronic illnesses can prevent or improve ED.
• Proactive lifestyle and medical management are essential.
• Emotional well-being is also a key factor.
• Addressing root causes offers the best long-term solution.

Such patients are at an increased risk of developing NAION again. Men with diabetes, radical prostatectomy, and other complicating factors may still benefit from treatment with a phosphodiesterase type-5 inhibitor such as Viagra. Patients who fail a trial of PDE5 inhibitor should be informed of the benefits and risks of other therapies. This of a different PDE5 inhibitor is unlikely to have a profound effect on sexual function and someone who fails a first drug trial, but should be considered in selected cases. Second-line therapies include intra-urethral suppositories, intra-cavernous drug injection, vacuum-constriction devices, and penile prosthesis. MUSE is an intra-urethral suppository of alprostadil, of vaso-active drug that relaxes smooth muscle in the penis and induces penile erection.

Can I Use Insurance?

Pharmacological, radiological, and psycho-physiological tests are used in efforts to determine the cause of ED. Intracavernosal injection, penile duplex Doppler ultrasonography, dynamic infusion cavernosometry and cavernosography, and internal pudendal arteriography all may be used to identify vasculogenic ED. Nocturnal penile tumescence testing can be useful to document an intact neurovascular axis, and the absence of nocturnal erectile activity may imply a neurogenic etiology. However, since the introduction of oral PDE-I therapy and the acceptance of goal-oriented therapy for most cases of ED, the rationale for extensive testing has weakened. For example, elderly patients may be less willing to undergo invasive testing for the evaluation and treatment libido for women of ED.

The Connection Between Erectile Dysfunction and Heart Disease

Only a small subset of men with ED benefit from vascular testing, which can identify specific arterial or venous dysfunction amenable to surgical reconstruction. For the vast majority, such testing is unlikely to change management strategy. Thus, specialized testing is now limited to PDE-I non-responders, young men with post-traumatic or primary ED, men with Peyronie’s Disease, and legal investigations. Treatment options for ED have evolved considerably over the past decade to encompass psychological counseling; oral, topical, intraurethral, and intracavernosal vasoactive therapy; oral therapies with other or unknown mechanisms; hormone replacement; vacuum constriction devices; and surgery, including vascular bypass procedures and penile implants. The goal of treatment is to restore satisfactory erections with minimal adverse effects. Although not as effective as intra-cavernosal penile injection, MUSE is a less invasive treatment option.

Key takeaways:

The best course of action to begin treatment for ED is to consult a healthcare provider. Your doctor will guide you in discovering which medication or alternative treatment will work best for your symptoms. Before coming in for an appointment, check out our free resource on how to prepare for your urologist appointment. This guide was made to help you feel prepared and comfortable when it comes time to see us here at Urology Specialist of the Carolinas. Click the button below to get access!

Resources created by teachers for teachers

It is estimated that erectile dysfunction (ED) affects as many as 30 million men in the United States. Patient interest in and treatment for ED surged with the introduction of oral phosphodiesterase-5 inhibitors (PDE-I) in 1998, and expenditures for office visits and other outpatient treatments increased during that time. The available data likely underestimate current treatment utilization given that in the 22 months after the first PDE-I, sildenafil (Viagra™), was launched, nearly 18 million prescriptions were filled at an approximate cost of $90 per 10-tablet prescription. The emergence of effective, convenient, and generally well-tolerated new treatment options (along with educational campaigns initiated by the pharmaceutical industry) has contributed to increased public awareness and a greater acceptability of and attention to the health and socioeconomic impacts of male sexual health. While ED is not life threatening, the condition may result in withdrawal from sexual intimacy, reduced quality of life, decreased working productivity, and increased healthcare utilization. An initial trial dose of intra-urethral alprostadil should be administered under healthcare provider supervision due to the risk of fainting. The cost of intra-urethral suppositories is high with respect to the overall success and therefore should be used judiciously.

Nearly 85% of men with erectile dysfunction in a clinical trial responded adequately enough to intra-cavernosal injection to have successful intercourse.